List view / Grid view
Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…
In EPR Issue 4, experts discuss implementing a global strategy to improve the sustainability of endotoxin testing, how to accelerate timelines for manufacture of multi-specific antibodies and the potential of oncolytic viruses as a therapy for glioblastoma. Also featured: progress towards smart vaccine manufacturing, an update on edible anticounterfeiting technology,…
As biopharmaceuticals become an increasingly important part of the drug development pipeline and market, EPR discusses key trends in the outsourcing of their manufacturing.
Growth in the global pharmaceutical contract manufacturing market will be driven by rising consumption of medicines and increasing commercialisation of generic and innovative therapies, among other factors.
bluebird bio’s Zynteglo (betibeglogene autotemcel), a one-time treatment for transfusion-dependent beta-thalassemia, will roll out with a $2.8mn price tag per dose.
Under a collaboration agreement Merck will pay Orna $150 million to support the progress of multiple oRNA vaccine and therapeutic programmes.
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
Here AMR Industry Alliance representatives Melissa Gong Mitchell and Steve Brooks discuss how the Alliance is mobilising the life sciences sector in combatting antimicrobial resistance (AMR). They present the newly established antibiotics manufacturing standard that aims to minimise pharma’s contribution to AMR in the environment, considering the critical considerations and…
The UK’s regulator approved Novartis’ radioligand therapy Pluvicto®▼ and radioactive diagnostic agent Locametz® for use in advanced prostate cancer.
Phase III trial results indicate BeiGene’s tislelizumab improved overall survival in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib.
EPR summarises research into the impact of gamma irradiation and ethylene oxide sterilisation treatments on European Pharmacopoeial compliance of common ophthalmic APIs.
![Close up of Amgen sign at its headquarters in Thousand Oaks, California, USA [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/amgen-2-e1660136652889-300x278.jpg)
![Close up of Amgen sign at its headquarters in Thousand Oaks, California, USA [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/amgen-2-e1660136652889.jpg)
The nearly $4bn ChemoCentryx acquisition will expand Amgen’s inflammation and nephrology portfolio and pipeline.
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
EPR discusses the findings of a recent study exploring whether microbicidal treatments using radiation cause the degradation of crude herbal medicinal components.
In this article, EPR’s Hannah Balfour discusses the recent multi-country monkeypox outbreak, highlighting key developments in the international response.
